At $38, CRISPR (CRSP) finds itself at the lower end of a price consolidation, as it attempts to define a price direction for the 3rd quarter of 2019. What is the outlook for the stock of a leader in the field of gene editing?
CRSP posted a 13.4% gain in April 2019 on the back of the fast track status granted to its drug CTX001 by the FDA, for the treatment transfusion-dependent beta thalassemia. This news enabled CRSP to push out from the downward channel to post some gains which found resistance at $40.27. Still, the opportunity within gene editing medicine has long-term investors intrigued.